PTGIR (Prostacyclin Receptor/IP) Drug Discovery Landscape & Assay Solutions
- By admin
- 23 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Pulmonary Arterial Hypertension & Vascular Protection Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PTGIR (IP receptor) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | PTGIR Full-Length ORF Lentivirus Premade Particles CMV promoter, Puromycin resistance, Titer >10^8 TU/ml. Sequence Verified. |
View PTGIR Products |
| Cellular System | PTGIR Stable Cell Line Construction Service HEK293 expressed (Native Glycosylation), Endotoxin Controlled. |
View PTGIR Products |
| Antigen | PTGIR Overexpressing Membrane Lysate High purity (>95%), Theoretical MW verified, Suitable for binding assays. |
View PTGIR Products |
| Benchmark Control | Anti-PTGIR Reference Antibody Recombinant positive control for assay calibration. |
View PTGIR Products |
| Validator | PTGIR siRNA Set (3 unique sequences) For knockdown verification and assay specificity control. |
View PTGIR Products |
| Related Target A | PTGER2 (EP2 Receptor) Synergistic cAMP pathway partner; Prostanoid family counter-screening essential. |
View PTGER2 Products |
| Related Target B | TBXA2R (Thromboxane A2 Receptor) Opposing physiological function; Critical for selectivity screening to avoid pro-thrombotic off-target effects. |
View TBXA2R Products |
| Related Target C | PTGER4 (EP4 Receptor) Similar cardioprotective signaling profile; Relevant for biased agonism studies. |
View PTGER4 Products |
| Related Target D | EDNRA (Endothelin Receptor A) Key for combination therapies in PAH; Endothelin pathway involvement. |
View EDNRA Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Native Conformation Preservation | Lentivirus particles for stable cell line construction; HEK293 expression ensures correct membrane insertion and glycosylation patterns |
| Cross-species Preclinical Translation (PAH models) | Human/Mouse/Rat/Cyno ortholog ORF available; Sequence-verified for homology modeling and compound profiling |
| Prostanoid Family Selectivity (EP1-4, TP) | Homolog panel (PTGER1-4, TBXA2R) proteins strictly verified by mass spec for counter-screening |
| Receptor Trafficking & Internalization | High-expression lentivirus suitable for flow cytometry-based internalization assays |
| Lack of Positive Controls | Clinical Benchmark Antibodies (Anti-PTGIR) included for assay calibration |
| False Positive Management | Validated siRNA included for knockdown verification and specificity control |
Live PTGIR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The PTGIR drug discovery landscape is shifting from first-generation prostacyclin analogs (e.g., epoprostenol, treprostinil) to next-generation oral selective non-prostanoid IP agonists (e.g., selexipag, ralinepag). Key R&D focus includes improving oral bioavailability, extending half-life, minimizing receptor desensitization through biased Gs/cAMP signaling, and expanding into combination therapies with PDE5 inhibitors and endothelin receptor antagonists (ERAs). Future indications may cover cardiovascular protection and anti-metastatic oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonists (Non-prostanoid) | J&J/Actelion (Selexipag), Altavant Sciences (Ralinepag) | PAH, CVD | Calcium Flux & cAMP Assay (Need stable PTGIR-expressing cell lines) |
| Prostacyclin Analogs | United Therapeutics (Treprostinil), GSK (Epoprostenol), Bayer, Liquidia | Severe PAH | Receptor Binding Assay (Need high-purity membrane preparations) |
| Combination Therapy (IP agonist + PDE5i/ERA) | Complex clinical protocols | Refractory PAH | Pathway Reporter Assay (Need validated, transduction-ready cell systems) |
| Targeted Delivery Systems | Emerging Biotechs (e.g., inhaled formulations) | Vasodilation, PAH | Selectivity Assay (Need related GPCR panels) |
Key Molecular Differentiation & Assay Strategy Insights
Developing best-in-class PTGIR agonists requires addressing: (1) biased agonism – favoring Gs/cAMP over β-arrestin to reduce desensitization; (2) >100-fold selectivity over EP2/EP4 to avoid off-target inflammation; (3) robust PK with oral bioavailability. Recommended assays include parallel cAMP accumulation (HTRF/AlphaScreen), calcium flux (FLIPR), and β-arrestin recruitment, alongside a prostanoid receptor counter-screen. TarMart’s lentivirus-based stable cell lines and validated membrane preparations provide the critical tools for these assays.